[Structure and action mechanism of sulfonylurea].
Tasaka
Yoshimasa
Y
Shizume Memorial Clinic.
D000255:Adenosine Triphosphate / Q000502:physiology; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D005089:Exocytosis / Q000187:drug effects; D005947:Glucose / Q000502:physiology; D051273:Glucose Transporter Type 2; D006801:Humans; D006943:Hyperglycemia / Q000139:chemically induced; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000166:cytology / Q000378:metabolism; D009004:Monosaccharide Transport Proteins / Q000378:metabolism; D015221:Potassium Channels / Q000502:physiology; D013453:Sulfonylurea Compounds / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology
D051273:Glucose Transporter Type 2; D007004:Hypoglycemic Agents; D007328:Insulin; D009004:Monosaccharide Transport Proteins; D015221:Potassium Channels; D013453:Sulfonylurea Compounds; D000255:Adenosine Triphosphate; D005947:Glucose